Journal of clinical medicine

Anti-Obesity Drugs Compared to Weight-Loss Surgery for Becoming Eligible for Heart Transplant in Patients with Heart Pumps

Updated

Abstract

Approximately 15% of left ventricular assist device (LVAD) recipients have a body mass index (BMI) of 35 kg/m² or greater.

  • The 2024 guidelines recommend weight loss to a BMI below 35 kg/m² as reasonable before listing for heart transplant.
  • Only 18.6% of patients achieve a 10% weight reduction through supportive care alone.
  • Anti-obesity medications like glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lead to gradual BMI reduction, with 26% of patients dropping below 35 kg/m² after one year.
  • Metabolic bariatric surgery can result in a BMI reduction of 6 to 10 kg/m² within 6 to 12 months and is associated with a threefold higher probability of subsequent transplantation.
  • Serious complications within 30 days occur in 11.3% of LVAD recipients undergoing surgery, compared to 2.5% of non-LVAD bariatric patients.
  • A selection framework is proposed to guide the choice between interventions based on factors like excess BMI, expected time on device, and risk profiles.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free